Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $13.5 billion.
- Teva Pharmaceutical Industries' Total Current Liabilities rose 515.79% to $13.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.5 billion, marking a year-over-year increase of 515.79%. This contributed to the annual value of $13.5 billion for FY2025, which is 515.79% up from last year.
- Teva Pharmaceutical Industries' Total Current Liabilities amounted to $13.5 billion in Q4 2025, which was up 515.79% from $11.5 billion recorded in Q3 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Total Current Liabilities peaked at $13.8 billion during Q3 2024, and registered a low of $10.4 billion during Q1 2023.
- Moreover, its 5-year median value for Total Current Liabilities was $11.8 billion (2021), whereas its average is $12.0 billion.
- In the last 5 years, Teva Pharmaceutical Industries' Total Current Liabilities soared by 3247.53% in 2024 and then plummeted by 1910.53% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Total Current Liabilities (Quarter) stood at $11.0 billion in 2021, then increased by 4.01% to $11.5 billion in 2022, then increased by 6.78% to $12.2 billion in 2023, then grew by 4.48% to $12.8 billion in 2024, then grew by 5.16% to $13.5 billion in 2025.
- Its Total Current Liabilities stands at $13.5 billion for Q4 2025, versus $11.5 billion for Q3 2025 and $11.9 billion for Q2 2025.